INTEGRATION OF BEVACIZUMAB IN METASTATIC COLORECTAL CANCER CHEMOTHERAPY REGIMENS IN 2 CLINICAL CENTERS IN MOSCOW AND SAINT PETERSBURG
The aim of this study was to estimate efficacy of first line chemotherapy with bevacizumab in metastatic colorectal cancer patients and investigate the impact of different prognostic factors on treatment outcome.Methods.During 2004–2008 48 colorectal cancer patients were included (29 in Russian N.N....
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
“ABV-press” Publishing house”, LLC
2015-02-01
|
| Series: | Тазовая хирургия и онкология |
| Subjects: | |
| Online Access: | https://ok.abvpress.ru/jour/article/view/99 |
| _version_ | 1827881682811748352 |
|---|---|
| author | N. V. Dobrova N. N. Semenov G. M. Manikhas N. Yu. Antimonik Yu. V. Vakhabova S. L. Gutorov |
| author_facet | N. V. Dobrova N. N. Semenov G. M. Manikhas N. Yu. Antimonik Yu. V. Vakhabova S. L. Gutorov |
| author_sort | N. V. Dobrova |
| collection | DOAJ |
| description | The aim of this study was to estimate efficacy of first line chemotherapy with bevacizumab in metastatic colorectal cancer patients and investigate the impact of different prognostic factors on treatment outcome.Methods.During 2004–2008 48 colorectal cancer patients were included (29 in Russian N.N. Blokhin Cancer Research Center, 19 in St. Petersburg), who had unresectable distant metastases. Primary tumor was resected in 93.8 % patients. 52.1 % had rectal cancer. 87.5 % had liver metastases, 43.8 % had more than 1 organ affected. 66.7 % received chemotherapy with bevacizumab 5 mg/kg biweekly, 33.3 % received bevacizumab 7,5 mg/kg every 3 weeks. 62.5 % patients had oxaliplatin-based regimens, 35.4 % – only fluorpyrimidines, 2.1 % – chemotherapy with irinotecan.Results.Median time of bevacizumab use was 7.8 months. 60.3 % had objective response, 87.4 % had stable diseases during more than 6 months. Median progression-free survival (PFS) was 11.5 months. Median overall survival (OS) was 24.1 months.Conclusions.Survival and efficacy results are comparable to international experience. Combination of fluorpyrimidines with bevacizumab had comparable efficacy to combined chemotherapy regimens with no impact on quality of life. Integration of bevacizumab in combined treatment regimens reduced the impact of negative prognostic factors on PFS and OS. |
| first_indexed | 2024-03-12T18:42:00Z |
| format | Article |
| id | doaj.art-a50609e0d07a48ba82192715a122ac21 |
| institution | Directory Open Access Journal |
| issn | 2686-9594 |
| language | Russian |
| last_indexed | 2024-03-12T18:42:00Z |
| publishDate | 2015-02-01 |
| publisher | “ABV-press” Publishing house”, LLC |
| record_format | Article |
| series | Тазовая хирургия и онкология |
| spelling | doaj.art-a50609e0d07a48ba82192715a122ac212023-08-02T07:48:57Zrus“ABV-press” Publishing house”, LLCТазовая хирургия и онкология2686-95942015-02-0104505610.17650/2220-3478-2013-0-4-50-5693INTEGRATION OF BEVACIZUMAB IN METASTATIC COLORECTAL CANCER CHEMOTHERAPY REGIMENS IN 2 CLINICAL CENTERS IN MOSCOW AND SAINT PETERSBURGN. V. Dobrova0N. N. Semenov1G. M. Manikhas2N. Yu. Antimonik3Yu. V. Vakhabova4S. L. Gutorov5N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowN.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowMunicipal Clinical Oncological Dispensary, Saint PetersburgMunicipal Clinical Oncological Dispensary, Saint PetersburgN.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowN.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowThe aim of this study was to estimate efficacy of first line chemotherapy with bevacizumab in metastatic colorectal cancer patients and investigate the impact of different prognostic factors on treatment outcome.Methods.During 2004–2008 48 colorectal cancer patients were included (29 in Russian N.N. Blokhin Cancer Research Center, 19 in St. Petersburg), who had unresectable distant metastases. Primary tumor was resected in 93.8 % patients. 52.1 % had rectal cancer. 87.5 % had liver metastases, 43.8 % had more than 1 organ affected. 66.7 % received chemotherapy with bevacizumab 5 mg/kg biweekly, 33.3 % received bevacizumab 7,5 mg/kg every 3 weeks. 62.5 % patients had oxaliplatin-based regimens, 35.4 % – only fluorpyrimidines, 2.1 % – chemotherapy with irinotecan.Results.Median time of bevacizumab use was 7.8 months. 60.3 % had objective response, 87.4 % had stable diseases during more than 6 months. Median progression-free survival (PFS) was 11.5 months. Median overall survival (OS) was 24.1 months.Conclusions.Survival and efficacy results are comparable to international experience. Combination of fluorpyrimidines with bevacizumab had comparable efficacy to combined chemotherapy regimens with no impact on quality of life. Integration of bevacizumab in combined treatment regimens reduced the impact of negative prognostic factors on PFS and OS.https://ok.abvpress.ru/jour/article/view/99colorectal cancerbevacizumabchemotherapyprognostic factors |
| spellingShingle | N. V. Dobrova N. N. Semenov G. M. Manikhas N. Yu. Antimonik Yu. V. Vakhabova S. L. Gutorov INTEGRATION OF BEVACIZUMAB IN METASTATIC COLORECTAL CANCER CHEMOTHERAPY REGIMENS IN 2 CLINICAL CENTERS IN MOSCOW AND SAINT PETERSBURG Тазовая хирургия и онкология colorectal cancer bevacizumab chemotherapy prognostic factors |
| title | INTEGRATION OF BEVACIZUMAB IN METASTATIC COLORECTAL CANCER CHEMOTHERAPY REGIMENS IN 2 CLINICAL CENTERS IN MOSCOW AND SAINT PETERSBURG |
| title_full | INTEGRATION OF BEVACIZUMAB IN METASTATIC COLORECTAL CANCER CHEMOTHERAPY REGIMENS IN 2 CLINICAL CENTERS IN MOSCOW AND SAINT PETERSBURG |
| title_fullStr | INTEGRATION OF BEVACIZUMAB IN METASTATIC COLORECTAL CANCER CHEMOTHERAPY REGIMENS IN 2 CLINICAL CENTERS IN MOSCOW AND SAINT PETERSBURG |
| title_full_unstemmed | INTEGRATION OF BEVACIZUMAB IN METASTATIC COLORECTAL CANCER CHEMOTHERAPY REGIMENS IN 2 CLINICAL CENTERS IN MOSCOW AND SAINT PETERSBURG |
| title_short | INTEGRATION OF BEVACIZUMAB IN METASTATIC COLORECTAL CANCER CHEMOTHERAPY REGIMENS IN 2 CLINICAL CENTERS IN MOSCOW AND SAINT PETERSBURG |
| title_sort | integration of bevacizumab in metastatic colorectal cancer chemotherapy regimens in 2 clinical centers in moscow and saint petersburg |
| topic | colorectal cancer bevacizumab chemotherapy prognostic factors |
| url | https://ok.abvpress.ru/jour/article/view/99 |
| work_keys_str_mv | AT nvdobrova integrationofbevacizumabinmetastaticcolorectalcancerchemotherapyregimensin2clinicalcentersinmoscowandsaintpetersburg AT nnsemenov integrationofbevacizumabinmetastaticcolorectalcancerchemotherapyregimensin2clinicalcentersinmoscowandsaintpetersburg AT gmmanikhas integrationofbevacizumabinmetastaticcolorectalcancerchemotherapyregimensin2clinicalcentersinmoscowandsaintpetersburg AT nyuantimonik integrationofbevacizumabinmetastaticcolorectalcancerchemotherapyregimensin2clinicalcentersinmoscowandsaintpetersburg AT yuvvakhabova integrationofbevacizumabinmetastaticcolorectalcancerchemotherapyregimensin2clinicalcentersinmoscowandsaintpetersburg AT slgutorov integrationofbevacizumabinmetastaticcolorectalcancerchemotherapyregimensin2clinicalcentersinmoscowandsaintpetersburg |